The risk for progression to high-grade dysplasia and esophageal adenocarcinoma was found to be increased in patients with both Barrett’s esophagus and confirmed persistent low-grade dysplasia ...

A study, published in Clinical Gastroenterology and Hepatology, identified the factors associated with Barrett's esophagus progression without dysplasia or Barrett's esophagus with low-grade dysplasia ...

The team investigated the incidence of both high-grade dysplasia and esophageal adenocarcinoma and compared progression in patients with various forms of low-grade dysplasia.

As technology continues to evolve, bringing AI, advanced imaging, and novel sampling techniques into routine practice, the ...

Data shows that using TissueCypher results can significantly improve management decisions for Barrett’s esophagus patients with low-grade dysplasia.

These cells can progress to a condition called dysplasia, which may in turn become cancer. Dysplasia is considered low-grade or high-grade, depending on the degree of cellular change.

Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the ...

The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with ...

“While the benefit is clear for patients with high-grade dysplasia, we suggest considering endoscopic eradication therapy for patients with low-grade dysplasia after clearly discussing the risks ...

Patients with low-grade dysplasia have around a one in 10 chance of developing esophageal cancer, but this risk doubles to one in five for high-grade dysplasia.

The low-grade version is linked with a one in 10 chance of developing esophageal cancer, while the high-grade version increases to a one in five chance. Continued monitoring of the esophagus is vital, ...

This cohort included 78 people with a normal esophagus, 77 with BE, 12 with high-grade dysplasia, five with low-grade dysplasia, one with indeterminate dysplasia and 61 with esophageal adenocarcinoma.